Originating in the 1990s, SBS Genetech was officially established in Beijing, the capital of China, in 2000. As highlighted in the article “Biopharma CRO industry in China: landscape and opportunities” published in Drug Discovery Today (impact factor: 8.4), SBS Genetech is recognized as one of the pioneering trio of enterprises marking the inception of China’s CRO industry and has witnessed the growth of Chinese biotechnology.
With SBS Genetech’s steadily growing influence, an increasing number of its products have found traction among international clients. Their maiden overseas recognition came in 2004 when a team from the International Rice Research Institute in the Philippines published in Theoretical and Applied Genetics (impact factor: 5.6). Today, SBS Genetech serves clients in over 60 countries, including renowned institutions like Harvard University, Imperial College London, National University of Singapore, University of Toronto, and Kyoto University, solidifying its reputation for trusted products globally.
Continually pushing the envelope, SBS Genetech has introduced a range of innovative products, some of which have been featured in top-tier journals like Science. Notable mentions include the GoodView™ Nucleic Acid Stain — a safer alternative to traditional ethidium bromide for nucleic acid detection in agarose gels — and Mutant Proteinase K, which offers enhanced specific activity and better room temperature stability. Additionally, the Bst P DNA/RNA Polymerase system, which uses a hot-start Aptamer with increased specificity at 70°C and supports primer-less amplification, has been gaining attention.
Several of these innovations have been pivotal in groundbreaking research. For instance, Professor Yigong Shi’s team from Westlake and Tsinghua Universities made a landmark discovery regarding the 3D structure of the activated human minor spliceosome, published in Science (impact factor: 41.84). Their research utilized SBS Genetech’s GoodView™ for nucleic acid staining in vitro splicing assays and RT-PCR.
During the COVID-19 crisis, SBS Genetech’s products played a crucial role. A team in Greece developed a real-time colorimetric LAMP device using SBS Genetech’s Bst DNA/RNA Polymerase, combining lab precision with user-friendliness. This device, with features like sub-30-minute analysis and a broad quantification range, showcased impressive sensitivity for detecting cancer mutations and COVID-19. Published in Scientific Reports (impact factor: 5.5), its cost-effectiveness and straightforward design position it as a globally preferred diagnostic tool.
Spanning over two decades, witnessing both China’s and the world’s biotech advancements, SBS Genetech continues to thrive and evolve. Market research by third-party institutions such as PR Newswire, Mordor Intelligence, and Business Wire positions SBS Genetech as a key player across domains like Gene Synthesis, Peptide Synthesis, Gene Editing, and Synthetic Biology, to name a few.
Emerging from the heart of China, SBS Genetech stands as a global biotechnological luminary. With an extensive portfolio that spans over 20 product categories—from gene synthesis and peptide synthesis to CRISPR gene editing and isothermal amplification—and boasting a remarkable assortment of over 10,000 SKUs, they are undeniably a force to be reckoned with. Committed to pushing the frontiers of science, SBS Genetech provides unparalleled life science solutions to researchers across the globe. Their profound belief? That through the power of biotechnology, the world stands on the brink of a brighter, better tomorrow. From China, for the World.